Kiniksa Pharmaceuticals SG&A Expense (Quarterly) Analysis

Kiniksa Pharmaceuticals Ltd (KNSA)

20.08 +0.70 (+3.61%) USD | NASDAQ | May 03, 16:00

20.08 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
March 31, 2024	38.68M
December 31, 2023	36.74M
September 30, 2023	34.47M
June 30, 2023	29.18M
March 31, 2023	29.04M
December 31, 2022	27.22M
September 30, 2022	24.68M
June 30, 2022	23.84M
March 31, 2022	22.22M
December 31, 2021	22.74M
September 30, 2021	20.76M
June 30, 2021	21.85M
March 31, 2021	20.60M
December 31, 2020	15.50M
September 30, 2020	11.80M

Date	Value
June 30, 2020	9.536M
March 31, 2020	8.486M
December 31, 2019	9.695M
September 30, 2019	8.432M
June 30, 2019	8.441M
March 31, 2019	8.394M
December 31, 2018	8.013M
September 30, 2018	5.515M
June 30, 2018	4.327M
March 31, 2018	3.71M
December 31, 2017	2.78M
September 30, 2017	2.241M
June 30, 2017	2.12M
March 31, 2017	1.903M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

8.432M

Minimum

Sep 2019

38.68M

Maximum

Mar 2024

21.19M

Average

22.03M

Median

SG&A Expense (Quarterly) Benchmarks